TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject requires surgical placement of one or two (adjacent) dental implants~* Ability to read and sign informed consent~* Males and females for 18-75 years of age~* Non-smokers~* Negative urine drug screen~Exclusion Criteria~* Advanced periodontal disease (\>20% Clinical Attachment Loss \>20% radiographic bone loss)~* History of bisphosphonate usage~* Medical history or medical condition that makes any of the study medications (naproxen sodium, acetaminophen, tramadol, etc.) inappropriate treatment options including any scheduled or recent cardiac procedures (within 6 months), a history of GI ulcers, liver or kidney disease, and anticoagulant or lithium intake.~* History of an allergic reaction to any pain reliever/fever reducer~* Contraindication to opioid use~* Positive urine drug screen for drugs of abuse unless on stable doses of a non-analgesic drug for a legitimate medical purpose~* Pregnancy - A urine pregnancy test will be performed immediately before the scheduled surgery on all women of child-bearing potential~* Local or systemic diseases that affects wound healing and inflammatory biomarkers (diabetes, autoimmune (rheumatoid arthritis), or inflammatory disorders - osteoarthritis is allowed).~* Smokers on this pilot study because it can affect levels of inflammatory biomarkers - a urine cotinine test will be performed immediately prior to the scheduled surgery on all subjects even if participant denies smoking history~* History of systemic steroid use over 2 weeks within last 2 years.~* Poor oral hygiene on a non-compliant individual.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen sodium (Type: EXPERIMENTAL): Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
- Acetaminophen (Type: ACTIVE_COMPARATOR): Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with obesity disease and inadequately controlled body weight with diet and/or exercise~* BMI ≥ 25 kg/m\^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35 kg/m\^2 at least one obesity-related comorbidity~* Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%~* Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female~* Visceral fat area ≥ 100 cm\^2~* Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study~Exclusion Criteria:~* Pregnancy or lactating women~* Use of pharmacologically active weight-loss medications~* Bariatric surgery~* Ketoacidosis, lactic acidosis, hyperosmolar coma~* Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to screening~* Gastro-intestinal (GI) disorders associated with chronic diarrhea~* Congestive heart failure, New York Heart Association (NYHA) class III or IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LIK066 2.5 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
- LIK066 10 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
- LIK066 25 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
- LIK066 50 mg (Type: EXPERIMENTAL): Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 75 years old~* Eligible for and co-enrolled on protocol UMN-2005LS036, for treatment of any of the following advanced hematologic malignancies:~  * Acute leukemias in complete remission (high risk CR1 or subsequent CR); chronic myelogenous leukemia (except refractory blast crisis); myelodysplastic syndrome with severe pancytopenia or complex cytogenetics, large-cell lymphoma, Hodgkin's lymphoma and multiple myeloma, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone b-cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia may be eligible after initial therapy.~* Have three partially HLA matched umbilical cord blood (UCB) units (1-2 units for UCB transplantation per MT2005-02 and 1 unit for the Treg cell infusion.)~* Adequate organ function~Exclusion Criteria:~* Patients not exposed to highly immunosuppressive single agent or multi-agent chemotherapy within 3 months, or an ablative preparative regimen for autologous hematopoietic stem cell transplant (HCT) within 1 year.~* Pregnancy or breastfeeding~* Current active serious infection~* Evidence of human immunodeficiency virus (HIV) or known HIV positive serology~* Patients with acute leukemia in morphologic relapse/persistent disease defined as \>5% blasts in a \> or = 15% cellular bone marrow or any % blasts if blasts have unique morphologic markers (e.g., Auer rods) or associated cytogenetic markers that allows morphologic relapse to be distinguished are not eligible.~* Chronic myelogenous leukemia in refractory blast crisis.~* Active central nervous system malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- UCB post-transplant Treg Cell Infusion (Type: EXPERIMENTAL): Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must provide informed consent~* Must agree to receive regular injections~* Must have current diagnosis of bipolar disorder I or II~* Must have at least four episodes of mood disorder in the last year that required psychiatric intervention~Exclusion Criteria:~* Female who is or may be pregnant or breastfeeding, who is not at least 1 year postmenopausal, or is not using reliable and adequate birth control~* Psychiatric diagnosis is due directly to effects of a substance or general medical condition~* Substance dependence~* Received treatment with a long-acting injectable antipsychotic less than 2 injection cycles prior to baseline (so, for example, if the drug is injected every 2 weeks, the patient could not enroll in the study if they had received an injection within the last 4 weeks)~* Received Electroconvulsive Therapy (ECT) within the last month~* Began psychotherapy (talk therapy) within 2 months~* In the past month was treated with any of these medications: carbamazepine, oxcarbazepine, fluoxetine, paroxetine, or clozapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): None
- 002 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* Aged 18 - 75 years~* Chronic low-back pain lasting at least for 6 months~* Hanover functional ability questionnaire (FFbH-R) score less than 70%~* At least one of the following diagnoses:~  1. Chronic lumbar ischialgia with or without radicular radiation~ 2. Chronic degenerative lumbar syndrome~ 3. Spondylarthrosis~ 4. Chronic facet syndrome~ 5. Lumbago with protrusion of the intervertebral disc~ 6. Lumbar radiculopathy~ 7. Lumbar and other intervertebral disc impairments with radiculopathy~ 8. Back pain at different locations of the spine~* Written, informed consent~Exclusion Criteria:~* Participation in another clinical trial/GCP-trial within 30 days prior to screening~* Participation in this trial in an earlier time~* Treatment with lymphdiaral basistropfen within 3 month prior to enrolment~* Pregnancy and lactation~* Non-compliance~* Incapability to understand the sense of the study~* Abuse of analgesics, opiates or other drugs~* Chronic pain that are as strong as or even stronger than the pain caused by the low-back and that need to be treated with analgesics~* Malign diseases~* Pathological neurological states~* Epilepsy~* Operation of the spine within 3 month prior to enrolment~* Fractures of the spine~* Bechterew's disease~* Alcohol abuse~* Consuming diseases~* Cachexia~* Palsy of the legs or anal sphincter due to acute impairment of the intervertebral disc~* Catheterisation or CT-controlled intra-articular injection in the lumbar region~* Hypersensitivity against one of the ingredients or excipients of the study drugs or against composite plants in general~* Systemic, progressive diseases like tuberculosis, leucosis, collagenosis, multiple sclerosis, acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, or other auto-immune diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lymphdiaral Basistropfen (HDC) (Type: EXPERIMENTAL): HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
- Placebo Solution (Type: PLACEBO_COMPARATOR): 10 drops t.i.d. for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive fibromatosis (desmoid tumor)~* Relapse or disease progression despite surgery, chemotherapy, radiotherapy, or any other treatment~* Tumors must meet the following criteria:~  * Ineligible for complete surgical resection by carcinological exeresis OR surgery would cause severe mutilation~ * Cannot be treated with curative radiotherapy~* Measurable disease by RECIST criteria~* No prior malignancy~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after completion of study treatment~* Absolute neutrophil count \> 1,000/mm\^3~* Platelet count \> 100,000/mm\^3~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* SGOT and SGPT \< 2.5 times ULN~* Creatinine ≤ 2.5 times normal~* No severe liver failure~* No chronic somatic or psychiatric illness that would preclude study compliance~* No known hypersensitivity to imatinib mesylate or one of its components~* No geographical, social, or psychological reason that would inhibit follow-up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent immunomodulators\*~* No concurrent hormonal treatments\* if used for fibromatosis~* No concurrent cytotoxic drugs\*~* No concurrent nonsteroidal anti-inflammatory drug\* if used for fibromatosis~  * Allowed if used as an analgesic 3 months prior to disease progression~* No concurrent participation in another therapeutic investigational trial NOTE: \*If disease progression has occurred during this treatment, then the treatment must have ended ≥ 1 month prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): 400 to 800 mg/day for a maximal 12 months study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (Bad Cholesterol) and Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Participants with hypercholesterolemia and hypertriglyceridemia.~* Participants had the following fasting lipid results following a greater than or equal to 12 hour fasting period (measured at the Screening Visit(s)):~  * Triglycerides level greater than or equal to 150 milligrams/deciliter (mg/dL) and less than 400 milligrams/deciliter, and~ * Low-density lipoprotein cholesterol greater than or equal to 160 milligrams/deciliter and less than or equal to 240 milligrams/deciliter.~Exclusion Criteria~* Participants with certain chronic or unstable medical conditions.~* Participants receiving coumarin anticoagulants, systemic cyclosporins, or certain other medications.~* Pregnant or lactating women, or women intending to become pregnant.~* Participants with diabetes mellitus that is poorly controlled.~* Participant was of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - ABT-143 capsules 5/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- B - ABT-143 capsules 10/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- C - ABT-143 capsules 20/135 mg (Type: EXPERIMENTAL): ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
- D - Simvastatin capsules 40 mg (Type: ACTIVE_COMPARATOR): Simvastatin capsules 40 mg daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed LN with ISN/RPS histopathology classes III to V~Exclusion Criteria:~* Patients with biopsy had proven ISN / RPS classes I, II and VI LN~* Patients with previous history of treatment and relapse of lupus nephritis~* Patients who were receiving continuous dialysis for more than two weeks prior to randomization.~* Patients of less than 12 years of age~* Patients who had concurrent infection or illness at the time of enrollment~* Patients who were taking concurrent medications which are supposed to have interactions with MMF or CYC~* Female patients who were pregnant and breastfeeding.~* Patients who did not give consent for participation

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
- mycophenolate mofetil (Type: EXPERIMENTAL): Patients in this arm received mycophenolate mofetil in the tablet form.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria include:~1. Participants who completed participation in study AMAG-FER-IDA-301 \[NCT01114139\]~2. Female participants of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study~Key Exclusion Criteria include:~1. Experienced a serious adverse event (SAE) related to ferumoxytol in study AMAG-FER-IDA-301~2. Female participants who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 \[NCT01114139\]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin \<11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) \<20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Baerveldt Versus ClearPath Comparison Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women with age at screening ≥ 18 years and ≤ 90 years~* Inadequately controlled glaucoma~* Valve-less aqueous shunt as the planned surgical procedure~* Patients with primary glaucomas or pseudoexfoliation, pigmentary and traumatic glaucoma with a previous failed trabeculectomy or other intraocular surgery included.~* Primary tubes included~* Investigators to recruit consecutively all eligible patients from their clinics.~* Superotemporal or inferonasal placement of the tube~* Capable and willing to provide consent~Exclusion Criteria:~* NLP~* Unable/unwilling to provide informed consent~* Unavailable for regular follow up~* Previous cyclodestructive procedure~* Prior scleral buckling procedure or other external impediment to supratemporal drainage device implantation~* Presence of silicone oil~* Vitreous in the anterior chamber sufficient to require a vitrectomy~* Uveitic glaucoma~* Neovascular glaucoma~* Nanophthalmos~* Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure~* Procedure combined with other surgery~* Any abnormality other than glaucoma in the study eye that could affect tonometry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Baerveldt 350 implant (Type: ACTIVE_COMPARATOR): None
- Ahmed ClearPath 350 implant (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 20-65 years~* Serum triglyceride \>150mg/dl AND/OR total cholesterol \>= 240mg/dl~Exclusion Criteria:~* Serum triglyceride \> 500 mg/dl~* Serum LDL-cholesterol at level which need drug treatment according to the patient risk categories (NCEP-ATP III)~* Diabetes mellitus~* Hypo. or hyperthyroidism~* Any systemic illnesses e.g. liver cirrhosis, acute or chronic renal failure, heart failure~* Use of drugs: OCPs, lipid lowering agents, thiazides~* Pregnancy~* Alcoholism~* History of allergic reaction to Somagh

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rhus (Type: EXPERIMENTAL): 500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule: 1 capsule twice daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete